<DOC>
	<DOCNO>NCT01410500</DOCNO>
	<brief_summary>The purpose study expand upon safety data carfilzomib providing expand access patient relapse refractory multiple myeloma unable enroll ongoing carfilzomib trial .</brief_summary>
	<brief_title>Carfilzomib Multiple Myeloma Expanded Access Protocol Patients With Relapsed Refractory Disease</brief_title>
	<detailed_description>This multi-center , expand access , open label study carfilzomib patient relapse refractory multiple myeloma . The study design provide access patient relapse refractory disease receive least 4 prior regimen eligible enrol carfilzomib Onyx-sponsored study enrol patient United States .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Histologically documented multiple myeloma 2 . Age ≥ 18 year 3 . ECOG status 02 . 4 . Life expectancy ≥3 month . 5 . Measurable disease , define one following : Serum Mprotein ≥1 g/dL . Urine Mprotein ≥200 mg/24 hour . For IgA patient whose disease reliably measure serum quantitative immunoglobulin ( qIgA ) , ≥750 mg/dl ( 0.75 g/dl ) . 6 . For oligosecretory nonsecretory MM , either follow : Measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( ie , magnetic resonance image [ MRI ] , compute tomography [ CT ] scan ) . Documented abnormal free light chain ratio ( NV : 0.26 1.65 ) value beyond laboratory calculation range . 7 . Received either refractory relapse discontinue due toxicity least 4 prior line therapy describe : immunomodulatory agent ( lenolidamide thalidomide ) bortezomib alkylating agent ( standard high dose ) corticosteroid 8 . Currently progressive disease . 9 . Refractory multiple myeloma define meet one following : Nonresponsive recent therapy ( eg , stable disease , progressive disease treatment ) . Disease progression within 60 day discontinuation recent therapy ( recent therapy must within 60 day Screening ) . 10 . LVEF ≥40 % within 30 day Cycle 1 Day 1 . 2D transthoracic ECHO prefer method evaluation ; MUGA acceptable ECHO available . 11 . Adequate hepatic function , define AST ( SGOT ) ALT ( SGPT ) &lt; 3 time upper limit normal serum bilirubin ≤2.5 mg/dl . 12 . Absolute neutrophil count ≥1,000 ( may support growth factor ) platelet count ≥40,000 within 14 day Cycle 1 Day 1 without transfusion . 13 . Creatinine clearance ( CrCl ) ≥15 mL/minute ( measure calculate use Cockcroft Gault Formula ) within 14 day Cycle 1 Day 1 . This criterion apply patient hemodialysis . 14 . Female patient childbearing potential must negative serum pregnancy test within 7 day Cycle 1 Day 1 must agree use dual contraception method duration treatment 3 month follow last dose treatment . Male patient must use effective barrier method contraception sexually active female childbearing potential treatment period 3 month follow last dose treatment . 15 . Written inform consent accordance federal , local , institutional guideline . 1 . Prior treatment carfilzomib enrollment Phase 3 carfilzomib trial . 2 . Known human immunodeficiency virus ( HIV ) seropositivity . 3 . Active infection require systemic treatment antibiotic , antiviral , antifungal . 4 . Known , active hepatitis A , B , C viral infection . 5 . Concomitant use approve investigational anticancer therapeutic agent , dexamethasone palliative radiation therapy . Patients receive radiation pain control eligible enrollment study . No washout period require antimyeloma treatment receive . 6 . Concomitant use investigational agent ( eg , antibiotic antiemetic ) . 7 . Pregnancy breastfeed . 8 . History plasma cell leukemia , define &gt; 2.0 × 10e9/L circulate plasma cell . 9 . History amyloidosis . 10 . Known history allergy Captisol® . 11 . Active congestive heart failure ( New York Heart Association Class 34 ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction within past 4 month . 12 . Intolerance hydration due preexist pulmonary , cardiac , renal impairment . Patients hemodialysis consider meeting criterion entry . 13 . Waldenström macroglobulemia IgM myeloma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>multiple myeloma</keyword>
</DOC>